Evaluation of a manual ELISA kit for determination of HER2/neu in serum of breast cancer patients

Anticancer Research

Volumn 28, Issue 5 B, 2008, Pages 3067-3073

  Gauchez, Anne Sophie ^a,b,c   Ravanel, Nadia ^a   Villemain, Danièle ^d   Brand, François Xavier ^a   Pasquier, Dominique ^a   Payan, Raoul ^e   Mousseau, Mireille ^b,c  

^a HÔpital Européen Georges Pompidou   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

^d UNIV GRENOBLE ALPES   (France)

^e Clinique Belledonne Saint Martin d'Hères   (France)

Author keywords

Breast carcinoma; HER2; HER2 neu ECD; Trastuzumab; Tumor marker

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ANALYTICAL ERROR; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CONTROLLED STUDY; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

EID: 55749083562     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Brand FX, Ravanel N, Gauchez AS, Pasquier D, Payan R, Fagret D and Mousseau M: Prospect for anti-HER2 receptor therapy in breast cancer. Anticancer Res 26: 715-722, 2006.
2. Rutin I and Yarden Y: The basic biology of HER2. Ann Oncol 12(suppl 1): 3-8, 2001.
3. Fehm T, Becker S, Duerr-Stoerzer S, Sotlar K, Mueller V, Wallwiener D, Lane N, Solomayer E and Uhr J: Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2-negative or of unknown HER2 status. Breast Cancer Res 9(5): R74, 2007.
4. Kong SY, Nam BH, Lee KS, Kwon Y, Lee ES, Seong MW, Lee do H and Ro J: Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin Chem 52(8): 1510-1515, 2006.
5. Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I, Pacifico E, Tofanetti FR, Sidoni A, Basurto C, Rulli A and Crino L: Evaluation of serum HER2 extracellular domain in early breast cancer patients; correlation with clinicopathological parameters and survival. Ann Oncol 19: 883-890, 2008.
6. Quaranta M, Daniele A, Coviello M, Savonarola A, Abbate I, Venneri MT, Paradiso A, Stea B, Zito A, Labriola A and Schittuli F: c-erbB-2 protein level in tissue and sera of breast cancer patients: a possible useful clinical correlation. Tumori 92: 311-317, 2006.
7. Hudelist G, Köstler W, Czerwenka K, Kubista E and Singer CF: Predicting the clinical course of breast cancer patients undergoing trastuzumab-based therapy: an outlook. Methods Find Exp Clin Pharmacol 26(3): 201-210, 2004.
8. Carney WP, Leitzel K, Ali S, Neumann R and Lipton A: HER-2/neu diagnostics in breast cancer. Breast Cancer Res 9: 207, 2007.
9. Kostler WJ, Steger GG, Soleinan A, Schwab B, Seiger CF, Tomek S, Brodowicz T, Krainer M, Wiltschke C, Horvat R, Jakesz R and Zelinski CC: Monitoring of serum HER2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer. Anticancer Res 24: 1127-1130, 2004.
10. Esteva FJ, Cheli CD, fritsche H, Former M, Slamon D, Thiel RP, Luftner D and Ghani F: Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 7(4): R436-443, 2005.
11. Maple L, Lathrop R, Bozich S, Harman W, Tacey R, Kelley M and Danilkovitch-Miagkova A: Development and validation of ELISA for herceptin detection in human serum. J Immunol Methods 295(1-2): 169-182, 2004.
12. Fehm T, Gebauer G, Jäger W: Clinical utility of serial serum c-erb-B2 determinations in the follow-up of breast cancer patients. Breast Cancer Res Treat 75: 97-106, 2002.
13. Streckfus C, Bigler L, Dellinger T, Dai X, Kingman A and Thigpen JT: The presence of soluble cerb-B2 in saliva and serum among women with breast carcinoma: a preliminary study. Clin Cancer Res 6: 2363-2370, 2000.
14. Lipton A, Ali SM, Leitzel K, Deniers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W and Allard J: Elevated serum HER2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20: 1467-1472, 2002.
15. Baselga J, Albanell J: Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 12: 535-541, 2001.
16. Ross JS, Fletcher JA, Linette GP, Stec J, Clark J, Ayers M, Symmans WF, Pusztai L and Bloom KJ: The HER2/neu gene and protein in breast cancer: biomarker and target of therapy. Oncologist 8: 307-325, 2003.
17. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S and Price CP: Potential clinical utility of serum HER2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 49: 1579-1598, 2003.
18. Asgeirsson KS, Agrawal A, Alien C, Hitch A, Ellis IO, Chapman C, Cheung K and Robertson JFR: Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. Breast Cancer Res 9(6): R75, 2007.
19. Kostler WJ, Schwab B, Singer CF, Neuman R, Rücklinger E, Brodowicz T, Tomek S, Niedermayr M, Hejna M, Steger GG, Krainer M, Wiltschke C and Zielinski CC: Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 10(5): 1618-1624, 2004.
20. Lipton A, Leitzel K, Ali SM, Dewers L, Harvey HA, Chaudri-Ross HA, Evans D, Lang R, Hacki W, Hamer P and Carney W: Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 104(2): 257-263, 2005.
21. Mazouni C, Hall A, Broglio K, Pritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L and Cristofanilli M: Kinetics of serum HER2/neu changes in patients with HER2 positive primary breast cancer after initiation of primary chemotherapy. Cancer 109: 496-501, 2007.
22. Colomer R, Llombart-Cussac A, Lloveras B, Ramos M, Mayordomo JI, Fernandez R, Tusquets I, Gil M, Barnadas A, Constensia M, Gilabert M and Alba E: High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study. Cancer 110(10): 2178-2185, 2007.
23. Mazouni C, Hall A, Broglio K, Fritsche H, Andre P, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L and Cristofallini M: Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 109(3): 496-501, 2007.
24. Muller V, Witzel I, Lück HA, Köhler G, von Minckwitz G, Möbus V, Sattler D, Wilczak W, Löning T, Jänicke F, Pantel K and Thomssen C: Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 86(1): 9-18, 2004.
25. Im SA, Kim SB, Lee MH, Im YH, Lee KH, Song HS, Lee MA, Lee J, Lee NS, Ham HS, Kim TY, Park YH, Lee KE, Kim KW, Seo JH, Lee SN, Hong YS, Bang YJ, Kim WK and Park HS: Docetaxel plus epirubicin as firstline chemotherapy in MBC (KCSG 01.10.05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor. Oncol Rep 14: 481-487, 2005.
26. Kostler WJ, Schwab B, Singer CF, Neumann R, Riechlinger E, Brodowicz T, Tomek S, Niedermayer M, Hejne M, Steger GG and Zelinski CC: Monitoring of serum HER2/neu predicts response and progression-free survival to trastuzumab based-treatment in patients with metastatic breast cancer. Clin Cancer Res 10: 1159-1160, 2004.
27. Former MN, Seidman AD, Schwartz MK, Ghani F, Thiel R, Norton L and Hadis C: Serum extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 16: 234-239, 2005.